A

Adcock Ingram Holdings Ltd
JSE:AIP

Watchlist Manager
Adcock Ingram Holdings Ltd
JSE:AIP
Watchlist
Price: 7 480.0003 Zac Market Closed
Market Cap: 12.1B Zac

Relative Value

There is not enough data to reliably calculate the relative value of AIP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AIP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
21.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
16.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
22.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
13
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
16.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
15.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
18.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
1.9

Multiples Across Competitors

AIP Competitors Multiples
Adcock Ingram Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ZA
Adcock Ingram Holdings Ltd
JSE:AIP
12.1B Zac 0 0 0 0
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.7 37.4 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
270.6B CHF 4.4 28.7 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
219.5B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
217.9B CHF 4.9 18.9 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.1 11.2 13
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.8B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average P/E: 25
Not Available
6%
N/A
US
Eli Lilly and Co
NYSE:LLY
55.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.1
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average EV/EBITDA: 440
Not Available
5%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average EV/EBIT: 1 883.7
Not Available
4%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5